Silo Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on February 12, 2021. The filing discloses the entry into a Material Definitive Agreement involving intellectual property licensing related to neuroinflammatory diseases.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of new contractual agreements.
Material Changes and Agreements
- Master License Agreement with University of Maryland, Baltimore (UMB):
- Silo Pharma secured an exclusive, worldwide, sublicensable, royalty-bearing license for intellectual property regarding "Central nervous system-homing peptides" for the treatment of multiple sclerosis and other neuroinflammatory pathologies.
- Financial Terms: Silo Pharma must pay UMB a license fee in the high five-digit figures, event-based milestone payments, royalties in the low to mid single digits based on net revenues, and a tiered percentage of sublicense income.
- Term: The agreement lasts until the later of patent expiration, data protection expiration, or ten years after the first commercial sale of a licensed product.
- Binding Letter of Intent with AIkido Pharma, Inc.:
- Silo Pharma agreed to grant AIkido a worldwide, exclusive sublicense of the UMB patents specifically for the therapeutic treatment of neuroinflammatory disease in cancer patients.
- Financial Terms: AIkido shall pay Silo Pharma a one-time license fee in the mid five-digit figures and the same royalty payments Silo Pharma owes to UMB.
- Status: The parties agreed to use best efforts to finalize the Sublicense arrangement as soon as reasonably possible, subject to UMB agreement terms.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance, management commentary on future performance, or specific risk factors beyond the standard contractual contingencies. The primary contingency noted is that the Sublicense with AIkido is subject to compliance with the terms of the UMB License Agreement.
Investor Verification Checklist
- Verify the exact dollar amounts for the "high five-digit" and "mid five-digit" license fees, as specific figures are redacted.
- Review the full text of the Master License Agreement (Exhibit 10.1) to understand specific milestone triggers and royalty calculation methodologies.
- Confirm the timeline for finalizing the binding Letter of Intent with AIkido Pharma into a definitive Sublicense agreement.
- Assess the competitive landscape for CNS-homing peptides in neuroinflammatory disease and multiple sclerosis.